TQB-3912 Market Summary

Key Factors Driving TQB-3912 Growth

1. Potentially differentiated targeted mechanism: TQB-3912 is an oral small-molecule protein kinase inhibitor being developed by Chia Tai Tianqing Pharmaceutical Group. Its development is focused on advanced solid tumors, where inhibition of the relevant kinase signaling pathway could interfere with cancer-cell survival, proliferation, migration and differentiation. The drug's oral formulation could support convenient chronic administration if efficacy is ultimately confirmed. The first-in-human study was specifically designed to characterize safety, pharmacokinetics, maximum tolerated dose and preliminary antitumor activity.

2. Clinical development has progressed beyond initial dose escalation: The Phase I study TQB3912-I-01 enrolled 36 patients with advanced malignant neoplasms and completed in May 2025. The study included dose escalation followed by dose-expansion/effectiveness exploration, with the objective of identifying a recommended dose for subsequent clinical development. Progression through a completed first-in-human program provides an important foundation for evaluating TQB-3912 in disease-specific trials.

3. Focus on HR-positive/HER2-negative breast cancer creates a large potential market: TQB-3912 has been investigated in combination with fulvestrant, with or without TQB3616, in patients with locally advanced or metastatic HR-positive/HER2-negative breast cancer. The study was designed to assess objective response rate, progression-free survival, duration of response, disease-control rate and overall survival. This population is commercially attractive because HR+/HER2− disease represents the largest molecular subtype of breast cancer and patients frequently develop resistance to endocrine-based treatment.

4. Combination therapy could provide a route to overcome endocrine resistance: The TQB-3912 program has explored combination treatment rather than relying solely on monotherapy. Combining TQB-3912 with fulvestrant is intended to target tumor growth through complementary biological mechanisms, while the additional TQB3616 combination represents an effort to build a multi-target regimen. If meaningful activity is demonstrated in endocrine-resistant disease, this could differentiate TQB-3912 from therapies that have limited effectiveness after progression on prior endocrine regimens.

5. Potential for development across multiple solid tumors: The initial Phase I study was not restricted to a single tumor type; it enrolled patients with advanced malignant tumors, allowing preliminary evaluation across a heterogeneous solid-tumor population. Such a basket-style early development strategy can identify tumor types showing greater sensitivity and subsequently guide disease-specific expansion studies. This approach may provide additional development opportunities if pharmacodynamic or clinical activity is observed outside breast cancer.

TQB-3912 Recent Developments

CTTQ is planning a multi-center Phase I/II trial targeting locally advanced or metastatic Hormone Receptor (HR)-positive and HER2-negative breast cancer. The study will evaluate TQB-3912 tablets administered in combination with fulvestrant injections, with or without CTTQ’s proprietary CDK4/6 inhibitor, TQB3616 capsules.

“TQB-3912 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of TQB-3912 for potential indication like HER2 negative breast cancer in the 7MM. A detailed picture of TQB-3912’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the TQB-3912 for potential indications. The TQB-3912 market report provides insights about TQB-3912’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current TQB-3912 performance, future market assessments inclusive of the TQB-3912 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of TQB-3912 sales forecasts, along with factors driving its market.

TQB-3912 Drug Summary

TQB-3912 is an investigational, orally bioavailable small-molecule inhibitor of AKT (protein kinase B) being developed by Chia Tai Tianqing Pharmaceutical Group (CTTQ) as a potential anticancer therapy. AKT is a central component of the PI3K/AKT/mTOR signaling pathway and regulates tumor-cell survival, proliferation, migration, metabolism, and differentiation; inhibition of this pathway by TQB-3912 is intended to suppress aberrant signaling and limit cancer-cell growth. The drug is administered orally in tablet form and has been evaluated in patients with advanced or metastatic malignancies. A Phase I study (NCT05997342) evaluated TQB-3912 in adults with advanced malignant tumors, with objectives including assessment of safety, tolerability, pharmacokinetics, maximum tolerated dose, and preliminary antitumor activity; the study enrolled 36 patients and was completed in May 2025. TQB-3912 has also been investigated in combination with fulvestrant, with or without the CDK4/6 inhibitor TQB3616, for locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer, although this Phase Ib/II study was subsequently terminated. Current public development information identifies advanced cancer and prostate cancer among its development areas, while the drug remains in early-stage clinical development and has no marketing approval. The report provides TQB-3912’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the TQB-3912 Market Report

The report provides insights into:

• A comprehensive product overview including the TQB-3912 MoA, description, dosage and administration, research and development activities in potential indication like HER2 negative breast cancer.
• Elaborated details on TQB-3912 regulatory milestones and other development activities have been provided in TQB-3912 market report.
• The report also highlights TQB-3912‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The TQB-3912 market report also covers the patents information, generic entry and impact on cost cut.
• The TQB-3912 market report contains current and forecasted TQB-3912 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The TQB-3912 market report also features the SWOT analysis with analyst views for TQB-3912 in potential indications.

Methodology

The TQB-3912 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TQB-3912 Analytical Perspective by DelveInsight

• In-depth TQB-3912 Market Assessment

This TQB-3912 sales market forecast report provides a detailed market assessment of TQB-3912 for potential indication like HER2 negative breast cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted TQB-3912 sales data uptil 2034.

• TQB-3912 Clinical Assessment

The TQB-3912 market report provides the clinical trials information of TQB-3912 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

TQB-3912 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

TQB-3912 Market Potential & Revenue Forecast

• Projected market size for the TQB-3912 and its key indications
• Estimated TQB-3912 sales potential (TQB-3912 peak sales forecasts)
• TQB-3912 Pricing strategies and reimbursement landscape

TQB-3912 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• TQB-3912 Market positioning compared to existing treatments
• TQB-3912 Strengths & weaknesses relative to competitors

TQB-3912 Regulatory & Commercial Milestones

• TQB-3912 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

TQB-3912 Clinical Differentiation

• TQB-3912 Efficacy & safety advantages over existing drugs
• TQB-3912 Unique selling points

TQB-3912 Market Report Highlights

• In the coming years, the TQB-3912 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The TQB-3912 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TQB-3912’s dominance.
• Other emerging products for HER2 negative breast cancer are expected to give tough market competition to TQB-3912 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TQB-3912 in potential indications.
• Analyse TQB-3912 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted TQB-3912 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TQB-3912 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of TQB-3912? How strong is TQB-3912’s clinical and commercial performance?
• What is TQB-3912’s clinical trial status in each individual indications such as HER2 negative breast cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TQB-3912 Manufacturers?
• What are the key designations that have been granted to TQB-3912 for potential indications? How are they going to impact TQB-3912’s penetration in various geographies?
• What is the current and forecasted TQB-3912 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of TQB-3912 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TQB-3912 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is TQB-3912? What is the duration of therapy and what are the geographical variations in cost per patient?